These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 10760427)

  • 81. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer.
    Liao Z; Komaki R; Stevens C; Kelly J; Fossella F; Lee JS; Allen P; Cox JD
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):558-65. PubMed ID: 12062597
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
    Yuan S; Sun X; Li M; Yu J; Ren R; Yu Y; Li J; Liu X; Wang R; Li B; Kong L; Yin Y
    Am J Clin Oncol; 2007 Jun; 30(3):239-44. PubMed ID: 17551299
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical and dosimetric risk factors of acute esophagitis in patients treated with 3-dimensional conformal radiotherapy for non-small-cell lung cancer.
    Zhang ZC; Xu J; Li BS; Zhou T; Lu J; Wang ZT; Li HS; Sun HF; Zhu J; Yu JM
    Am J Clin Oncol; 2010 Jun; 33(3):271-5. PubMed ID: 19823071
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study.
    Fukuda M; Soda H; Fukuda M; Kinoshita A; Nakamura Y; Nagashima S; Takatani H; Tsukamoto K; Kohno S; Oka M
    Cancer; 2007 Aug; 110(3):606-13. PubMed ID: 17577234
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
    Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
    J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Reply to "Radiation pneumonitis and docetaxel".
    Senan S
    Lung Cancer; 2004 Jan; 43(1):117-8; author reply 119-20. PubMed ID: 14698546
    [No Abstract]   [Full Text] [Related]  

  • 90. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
    Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
    Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer.
    Schild SE; Wong WW; Vora SA; Halyard MY; Wheeler RH
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):729-34. PubMed ID: 12377324
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.
    Su S; Li T; Lu B; Wang X; Li J; Chen M; Lu Y; Bai Y; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):769-77. PubMed ID: 26530745
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies.
    Cox JD; Sause WT; Byhardt RW; Komaki R; Perez CA; Pajak TF
    Lung Cancer; 1994 Mar; 10 Suppl 1():S161-6. PubMed ID: 8087506
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer.
    Shioyama Y; Tokuuye K; Okumura T; Kagei K; Sugahara S; Ohara K; Akine Y; Ishikawa S; Satoh H; Sekizawa K
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):7-13. PubMed ID: 12694818
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.
    Le Chevalier T; Arriagada R; Quoix E; Ruffie P; Martin M; Douillard JY; Tarayre M; Lacombe-Terrier MJ; Laplanche A
    Lung Cancer; 1994 Mar; 10 Suppl 1():S239-44. PubMed ID: 8087515
    [TBL] [Abstract][Full Text] [Related]  

  • 98. No thoracic radiation myelitis after spinal cord dose > or = 50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with Stage III non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy.
    Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Aleksandrovic J; Nikolic N; Igrutinovic I
    Lung Cancer; 2002 Mar; 35(3):287-92. PubMed ID: 11844603
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy.
    Ball D; Smith J; Wirth A; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1007-13. PubMed ID: 12419426
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.
    Komaki R; Pajak TF; Byhardt RW; Emami B; Asbell SO; Roach M; Pedersen JE; Curran WJ; Lattin P; Russell AH
    Lung Cancer; 1993 Dec; 10(3-4):189-97. PubMed ID: 8075966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.